

# Clinical Practice Research Datalink (CPRD) GOLD

**First published:** 01/02/2024

**Last updated:** 22/04/2024

Data source

Primary care medical records

## Administrative details

### Administrative details

**PURI**

<https://redirect.ema.europa.eu/resource/1111113>

**Data source ID**

1111113

**Data source acronym**

CPRD GOLD

**Data holder**

[Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences \(NDORMS\), University of Oxford](#)

**Data source type**

Primary care medical records

**Main financial support**

National, regional, or municipal public funding

**Care setting**

Primary care – GP, community pharmacist level

**Data source qualification**

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

---

#### Data source website

<https://cprd.com/data-highlights>

## Contact details

Antonella Delmestri



[antonella.delmestri@ndorms.ox.ac.uk](mailto:antonella.delmestri@ndorms.ox.ac.uk)

## Data source regions and languages

#### Data source countries

United Kingdom

---

#### Data source languages

English

---

#### Data source regions

England

Northern Ireland

Scotland

Wales [Cymru GB-CYM]

## Data source establishment

#### Data source established

09/09/1987

---

#### Data source time span

**First collection:** 09/09/1987

The date when data started to be collected or extracted.

## Publications

### Data source publications

[The General Practice Research Database: Now and the Future \(2007\)](#)

The accuracy of date of death recording in the Clinical Practice Research Datalink GOLD database in England compared with the Office for National Statistics death registrations (2019)

Data Resource Profile: Clinical Practice Research Datalink (CPRD) (2015)

Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource (2012)

The General Practice Research Database: Role in Pharmacovigilance (2004)

## Studies

### List of studies that have been conducted using the data source

DARWIN EU® Characterization of patients with chronic hepatitis B and C

Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids: Protopic JOint European Longitudinal Lymphoma and skin cancer Evaluation (JOELLE) Study

DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus

DARWIN EU® EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the context of the OMICRON variant

DARWIN EU® Drug utilisation study of medicines with prokinetic properties in children and adults diagnosed with gastroparesis

DARWIN EU® Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations

DARWIN EU® Rates of occurrence of treatment-related intercurrent events in patients with major depressive disorder

DARWIN EU® Effectiveness of COVID-19 vaccines on severe COVID-19 and post acute outcomes of SARS-CoV-2 infection

DARWIN EU® Age specific incidence rates of RSV related disease in Europe

DARWIN EU® Monitoring prescription of medicines for public health emergencies at risk of shortages

DARWIN EU® Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer

DARWIN EU® Comparing direct and indirect methods to estimate prevalence of chronic diseases using real-world data

DARWIN EU® – Frailty and polypharmacy among adults with selected cancers at the time of diagnosis

DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023

DARWIN EU® - Characterising interstitial lung disease in Europe

SAFETY-VAC: a framework for the post-authorisation safety monitoring and evaluation of vaccines in the European Union (SAFETY-VAC)

The utilisation of antiepileptics in men and women of childbearing age, and pregnant women in Europe (ADEPT)

DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications

DARWIN EU® - Drug Utilisation Study on GLP-1 Receptor Agonists

SAFETY-VAC: a framework for the postauthorisation safety monitoring and evaluation of vaccines in the European Union (SAFETY-VAC)

## Data elements collected

### The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

---

#### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

Yes

---

#### **Pregnancy and/or neonates**

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

---

#### **Hospital admission and/or discharge**

Yes

---

**ICU admission**

Is information on intensive care unit admission available?

Yes

---

**Cause of death**

Not Captured

---

**Prescriptions of medicines**

Captured

---

**Dispensing of medicines**

Not Captured

---

**Advance therapy medicinal products (ATMP)**

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

---

**Contraception**

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

Yes

---

**Indication for use**

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

---

**Indication vocabulary**

Read

---

**Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

Yes

---

**Administration of vaccines**

Yes

---

**Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

---

## Procedures vocabulary

Read

---

### Healthcare provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

---

### Clinical measurements

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

---

### Genetic data

Are data related to genotyping, genome sequencing available?

Not Captured

---

### Biomarker data

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Not Captured

---

### Patient-reported outcomes

Is information on patient-reported outcomes (e.g., quality of life) available?

No

---

### Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

No

---

### Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

No

---

### Unique identifier for persons

Are patients uniquely identified in the data source?

Yes

---

## **Diagnostic codes**

Captured

---

## **Diagnosis / medical event vocabulary**

Read

---

## **Medicinal product information**

Captured

---

## **Medicinal product information collected**

Active ingredient(s)

Brand name

Formulation

Route of administration

Strength

---

## **Medicinal product vocabulary**

dm+d

Gemscript

---

## **Quality of life measurements**

Not Captured

---

## **Lifestyle factors**

Captured

---

## **Lifestyle factors**

Alcohol use

Diet

Tobacco use

---

## **Sociodemographic information**

Captured

---

## **Sociodemographic information collected**

Age

Ethnicity

Gender

Marital status

---

Quantitative descriptors

Population Qualitative Data

## Population age groups

Paediatric Population (< 18 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (? 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

## Estimated percentage of the population covered by the data source in the catchment area

In CPRD GOLD January 2023 there were 2,965,915 current acceptable patients (i.e. registered at currently contributing practices that use Vision software, excluding transferred out, deceased patients and those flagged by CPRD as not acceptable for clinical research for data quality issues) equal to 4.42% based on the UK population estimates of 67,081,000 from the Office of National Statistics (January 2023). Our CDM data include 2,965,378 after excluding 537 patients as described for the full population below: the percentage remains the same.

---

## Description of the population covered by the data source in the catchment area

### whose data are not collected (e.g., people who are registered only for private care)

CPRD GOLD January 2023 included 24,021,212 patients of which 2,877,893 were flagged as not acceptable for clinical research. Our CDM data include 17,216,081 by excluding those and also patients with gender not equal to Male or Female (1,107), year of birth before 1875 (3), practice up-to-standard after the patient died or left the practice (410,502) or no observation (3,515,626). The numbers below refer to this CDM population.

## Population

### Population size

17216081

## Active population

### Active population size

2965378

## Median observation time



**Median time (years) between first and last available records for unique individuals captured in the data source**

5.82

---

**Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt**

13.21

---

## Data flows and management

### Access and validation

#### **Governance details**

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

<https://cprd.com/>

#### **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

---

#### **Access to subject details**

Can individual patients/practitioners/practices included in the data source be contacted?

No

---

#### **Description of data collection**

<https://cprd.com/primary-care-data-public-health-research>

## Event triggering registration

#### **Event triggering registration of a person in the data source**

Practice registration

---

#### **Event triggering de-registration of a person in the data source**

Death

Practice deregistration

## Data source linkage

## Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

Yes

---

## Linkage description, possible linkage

<https://cprd.com/cprd-linked-data#Data%20from%20NHS%20Digital>

## Linked data sources

### Pre linked

Is the data source described created by the linkage of other data sources?

No

---

### Data source, other

Hospital Episode Statistics (HES): HES Accepted Patient Care (APC), HES Accident & Emergency (A&E), HES Outpatient (OP). Office of National Statistics (ONS) mortality records. Index of Multiple Deprivation (IMD), Townsend index, Carstairs index, Rural Urban classification

---

### Linkage variable

Patient identifier

## Data management specifications that apply for the data source

### Data source refresh

Every 6 months

---

### Informed consent for use of data for research

Other

---

### Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

---

### Data source preservation

Are records preserved in the data source indefinitely?

Yes

---

### **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

Yes

---

### **Informed consent, other**

Patient are assumed to consent, but they can withdraw consent at any time

---

### **Data source last refresh**

01/07/2023

## **Common Data Model (CDM) mapping**

### **CDM mapping**

Has the data source been converted (ETL-ed) to a common data model?

Yes

### **CDM Mappings**

#### **CDM name**

OMOP

---

#### **CDM website**

<https://www.ohdsi.org/Data-standardization/>

#### **Data source ETL CDM version**

5.32, with plan to use 5.4 in the next ETL

---

#### **Data source ETL frequency**

6,00 months

---

#### **Data source ETL status**

Completed

---

#### **Data source ETL specifications (link)**

<https://ohdsi.github.io/ETL-LambdaBuilder/docs/CPRD>